Joseph Eckman Email & Phone Number

North Chicago, Illinois, US

• A motivated Pharmacologist II in the In Vivo Tumor Biology group dedicated to the discovery and development of innovative therapeutics, both small molecule and biologics. As part of a multidisciplinary team, perform in.
• Perform in vivo studies and incorporate pharmacological skills (dosing, surgery, imaging and collection/processing of blood/tissues) to evaluate the efficacy of novel agents.
• Contribute and lead development of new disease models and explore disease mechanisms and mechanisms of drug action
• Perform supporting assays (cytokine profiling, ELISA and western blot analysis of tissue lysates, cell culture, etc.) to assess target modulation levels and downstream effects
• Demonstrate a high level of initiative in troubleshooting experiments and performing data analysis
• Effectively collaborate across all intra and cross functional teams

• Assessed antitumor and PK/PD relationship of novel Peptide Drug Conjugates (PDCs) and small molecules directed against oncology targets in various in vivo, ex vivo, and in vitro studies. Data generated has contributed.
• Established multiple xenograft and syngeneic mouse models of various cancers for evaluation of compound efficacy
• Assisted with establishment of intracranial model of murine glioma and performed image analysis using IVIS (Xenogen) to track tumor development
• Evaluated antitumor activity of compounds in various models of human cancer
• Performed in-life portion of various tissue distribution, PK/PD and safety/toxicity studies in collaboration with various groups within Eisai
• Performed cell culture and generation of cell banking stocks for multiple cancer cell lines

• In vivo, ex vivo and in vitro inflammation model development and validation and small molecule compound screening for efficacy and PK/PD relationship evaluation and drug candidate selection in multiple projects.
• Established Air Pouch and Intraperitoneal inflammation PK/PD models in rat and performed compound evaluation in these models
• Established MRL/lpr lupus model, performed compound evaluation, and coordinated sample analysis among multiple sites in Merck Research Laboratories
• Set up analyses using Advia hematologic system, flow cytometry, ELISA, differential cell count, cell surface marker and cytokine measurement
• Performed microtitration of compounds via ECHO and stimulation of rat blood via Biomek for HTS screening of small molecules and advancement of hits to in vivo disease models
• Trained junior scientists in disease monitoring and sample analysis

Basel, Baselstadt, CH

• In vivo, ex vivo and in vitro Oncology models for efficacy and PK/PD studies for the advancement of small molecules and antibodies.
• Performed reconstruction of trabecular and cortical bone environment in live mouse (SCANCO uCT)
• Analyzed metastases in live mouse models (Xenogen IVIS200)
• Established and performed chronic Xenograft studies for characterization and advancement of select small molecules and antibodies
• Performed ATD, MTD, PK/PD and efficacy studies for project compounds
• Generated data that expedited the decision processes of moving the HDAC inhibitor project and DR5A-Ab project toward POC status

Brussels, BE

• Assay development and model establishment and small molecule compound evaluation for asthma/allergy indications
• Set up and performed the human whole blood donor program on- site
• Established the human whole blood assay to screen small molecule potencies and advance hits to animal models
• Performed whole cell radiolabeled-ligand binding studies to characterize novel small molecules in the CCR2, CCR4 and CCR8 antagonist projects (Published)
• Conducted nociception in vivo studies for characterizing the novel analgesia project compound epibatidine (Published)
• Established and performed ATD, MTD, PK/PD studies for select projects